Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.

Leukemia & lymphoma - 1 May 2017

Francke Silvan, Mies Anna, Meggendorfer Manja, Oelschlaegel Uta, Balaian Ekaterina, Gloaguen Silke, Haferlach Torsten, Ehninger Gerhard, Bornhäuser Martin, Platzbecker Uwe

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to Bone Marrow
Share to Janus Kinase 2
Share to Leukemia, Myelomonocytic, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Nitriles

Share to Pyrazoles

Share to Pyrimidines

Source

Identifiers

PMID: 27659716
DOI: 10.1080/10428194.2016.1225209

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.PMID 27659716Read ↗

JAK inhibitors for the treatment of myeloproliferative neoplasms and other disordersSemantic proximity Read ↗

Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genesSemantic proximity Read ↗

A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).Semantic proximity Read ↗

JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.Semantic proximity Read ↗

Janus kinase inhibition and symptom control in myeloproliferative neoplasmsSemantic proximity Read ↗

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.Semantic proximity Read ↗

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway AlterationsSemantic proximity Read ↗

Janus activated kinase inhibition in myelofibrosis.Semantic proximity Read ↗

Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.Semantic proximity Read ↗

Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications.Semantic proximity Read ↗

Challenges Facing JAK Inhibitor Therapy for Myeloproliferative NeoplasmsSemantic proximity Read ↗

JAK2 inhibitors and myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.